GFT505: Phase II data

The single-blind, crossover, French Phase II GFT505-210-6 trial in 22 insulin-resistant patients with abdominal obesity showed that once-daily 80 mg oral GFT505 met the co-primary endpoints of significantly increasing insulin sensitivity in the liver and peripheral tissues from baseline to week 8 vs. placebo. Specifically, GFT505 significantly reduced insulin-induced hepatic glucose production by 0.86 mg/kg/min vs. 0.63 mg/kg/min for placebo (p=0.006), and significantly increased glucose infusion rate by 3.8 mg/kg/min vs. 3.2 mg/kg/min for placebo (p=0.019). Genfit said the reduction in hepatic glucose production is equivalent to an improvement in liver insulin response of 37%. ...